The French Competition Authority sanctions a laboratory for having abused of its dominant position in the market for certain medicinal products intended for hospitals (Sandoz laboratories)

Press Release published on the official website of the French Competition Authority.

Laboratoires SANDOZ sanctioned for abusing their monopoly in the cyclosporin market.* In a decision dated 24th July, 2003, the Conseil de la concurrence imposed sanctions on laboratoires SANDOZ (which has now become NOVARTIS Pharma SA) for abuse of a dominant position, and fined them a sum of 7.8 million Euros. Laboratoires Sandoz' monopoly in the cyclosporin market Laboratoires Sandoz manufacture and market amongst others two proprietary medicinal products. These products, Sandimmun® and Néoral®, are both patented and are based on the same active ingredient, cyclosporin. They are

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority sanctions a laboratory for having abused of its dominant position in the market for certain medicinal products intended for hospitals (Sandoz laboratories), 24 July 2003, e-Competitions Bulletin Rebates, Art. N° 61679

Visites 105

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues